BACKGROUND: An impediment to mucositis research has been the lack of an accepted, validated scoring system. The objective of this study was to design, test, and validate a new scoring system for mucositis that can be used easily, is reproducible, and provides an accurate system for research applications. METHODS: A panel of experts, convened to design an objective, simple, and reproducible assessment tool to evaluate mucositis with specific application to multicenter clinical trials, developed a scale that measured objective and subjective indicators of mucositis. Nine centers participated in the study's validation. Paired investigators at each center evaluated patients receiving chemotherapy or head and neck radiation. Objective measures of mucositis evaluated ulceration/pseudomembrane formation and erythema. Subjective outcomes of mouth pain, ability to swallow, and function were measured. Analgesia use for mouth sensitivity was recorded. RESULTS: One hundred eight chemotherapy and 56 radiation therapy patients were evaluated. Seventy-eight percent of chemotherapy patients and 64% of radiation therapy patients had clinically significant mucositis. Cumulative daily mucositis scores demonstrated a high correlation among observers. Using area under the curve analysis, it was found that for chemotherapy patients, the highest correlations (correlation coefficient > 0.92) occurred for the scores that selected the three highest daily values over the course of mucositis assessment. High interobserver correlations were noted for patients receiving radiation therapy. Objective mucositis scores demonstrated strong correlation with symptoms. CONCLUSIONS: The scoring system evaluated was easily used, showed high interobserver reproducibility, was responsive over time, and measured those elements deemed to be associated with mucositis. The use of concomitant symptomatic measurements appeared to be unnecessary.
BACKGROUND: An impediment to mucositis research has been the lack of an accepted, validated scoring system. The objective of this study was to design, test, and validate a new scoring system for mucositis that can be used easily, is reproducible, and provides an accurate system for research applications. METHODS: A panel of experts, convened to design an objective, simple, and reproducible assessment tool to evaluate mucositis with specific application to multicenter clinical trials, developed a scale that measured objective and subjective indicators of mucositis. Nine centers participated in the study's validation. Paired investigators at each center evaluated patients receiving chemotherapy or head and neck radiation. Objective measures of mucositis evaluated ulceration/pseudomembrane formation and erythema. Subjective outcomes of mouth pain, ability to swallow, and function were measured. Analgesia use for mouth sensitivity was recorded. RESULTS: One hundred eight chemotherapy and 56 radiation therapy patients were evaluated. Seventy-eight percent of chemotherapy patients and 64% of radiation therapy patients had clinically significant mucositis. Cumulative daily mucositis scores demonstrated a high correlation among observers. Using area under the curve analysis, it was found that for chemotherapy patients, the highest correlations (correlation coefficient > 0.92) occurred for the scores that selected the three highest daily values over the course of mucositis assessment. High interobserver correlations were noted for patients receiving radiation therapy. Objective mucositis scores demonstrated strong correlation with symptoms. CONCLUSIONS: The scoring system evaluated was easily used, showed high interobserver reproducibility, was responsive over time, and measured those elements deemed to be associated with mucositis. The use of concomitant symptomatic measurements appeared to be unnecessary.
Authors: Giuseppe Masucci; Peter Broman; Charles Kelly; Sten Lindahl; Lena Malmberg; Johan Reizenstein; Martin Alenius; Rolf Lewensohn Journal: Med Oncol Date: 2005 Impact factor: 3.064
Authors: Rajesh V Lalla; Linda E Choquette; Kathleen F Curley; Robert J Dowsett; Richard S Feinn; Upendra P Hegde; Carol C Pilbeam; Andrew L Salner; Stephen T Sonis; Douglas E Peterson Journal: Oral Oncol Date: 2014-08-21 Impact factor: 5.337
Authors: J E Lau; C Weber; M Earl; L A Rybicki; K D Carlstrom; C M Wenzell; B T Hill; N S Majhail; M Kalaycio Journal: Bone Marrow Transplant Date: 2015-02-09 Impact factor: 5.483
Authors: Deborah Tomlinson; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; Lillian Sung Journal: Support Care Cancer Date: 2007-08-28 Impact factor: 3.603
Authors: Corey Cutler; Brent Logan; Ryotaro Nakamura; Laura Johnston; Sung Choi; David Porter; William J Hogan; Marcelo Pasquini; Margaret L MacMillan; Jack W Hsu; Edmund K Waller; Stephan Grupp; Philip McCarthy; Juan Wu; Zhen-Huan Hu; Shelly L Carter; Mary M Horowitz; Joseph H Antin Journal: Blood Date: 2014-06-30 Impact factor: 22.113